StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Propranolol

HCID 4946
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
13013-17-7
Standard-SMILES
CC(C)NCC(O)COc1cccc2ccccc12
InChIKey
AQHHHDLHHXJYJD-UHFFFAOYSA-N
Summenformel
C16H21NO2
Durchschnittliche Molmasse
259,34 g/mol
Monoisotopische Masse
259,15722891

Überblick

Propranolol is a propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3. It has a role as an anxiolytic drug, a beta-adrenergic antagonist, a vasodilator agent, an antihypertensive agent, a xenobiotic, an anti-arrhythmia drug, an environmental contaminant and a human blood serum metabolite. It is a member of naphthalenes, a secondary amine and a propanolamine. It is functionally related to a 1-naphthol.

Namen und Bezeichner

Bevorzugter Name
Propranolol
IUPAC
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
Lokaler Name
Propranolol
Englischer Name
Propanolol
Summenformel
C16H21NO2
Molmasse
259.34

Namen und Synonyme

propranolol525-66-6Propanololbeta-PropranololBetalongEuprovasinProprasylytReducorPropanalolAnaprilinepropranololodl-propranolol
Weitere Namen anzeigen
Avlocardylrac-PropanololAvlocanol208-378-0
Propranololum1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol9Y8NXQ24VQ1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-CHEBI:8499DTXSID6023525

Datenbank-Bezeichner

CAS
13013-17-7、525-66-6
PubChem CID
4946
DTXSID
DTXSID6023525
ChEMBL
CHEMBL27
ChEBI
CHEBI:8499
UNII
9Y8NXQ24VQ
EC Number
208-378-0、235-867-6
Nikkaji
J6.653B

Eigenschaften

Berechnete Struktureigenschaften

XLogP
3
Polarare Oberfläche (TPSA)
41,5 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
6
Schwere Atome
19
Formalladung
0
Komplexität
257

Experimentelle und physikochemische Eigenschaften

Chemical Classes · 2 Einträge

Other Uses -> Pharmaceuticals

Pharmaceutical

Drugs · 3 Einträge

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Antihypertensive drugs

Pharmaceuticals

LogP · 2 Einträge

3.48

3.09

Solubility0.0617 mg/L at 25 °C
Human Drugs · 5 Einträge

Antidepressants -> Beta blockers

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics

EMA approved medicines: Human medicine

Pharmaceuticals

Antianginal medicines

Melting Point96 °C
Physical DescriptionSolid
Ionization Efficiency · 6 Einträge

Positive

3.75

2.7

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory Information · 2 Einträge

REACH registered substance: (±)-1-(isopropylamino)-3-(naphthyloxy)propan-2-ol (EC: 235-867-6)

Propranolol: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-: Human health tier I assessment
Hazards SummaryAllergic contact dermatitis reported in pharmaceutical workers; [Kanerva, p. 1830] See Oxprenolol.
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Mild-to-moderate elevations in serum aminotransferase levels occur in less than 2% of patients on propranolol and are usually transient and asymptomatic, resolving even with continuation of therapy. Despite its widespread use, propranolol has not been convincingly linked to instances of clinically apparent liver injury; the few cases reported have generally occurred in patients who were receiving other well known hepatotoxic agents or were associated with elevations in serum enzymes only without jaundice.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

C07AA05

C - Cardiovascular system

QC - Cardiovascular system

C07AA05

Protein BindingApproximately 90% of propranolol is protein bound in plasma. Other studies have reported ranges of 85-96%.
Pharmacodynamics · 1 Eintrag

Propranolol is a beta-adrenergic receptor antagonist used to treat hypertension. Propranolol has a long duration of action as it is given once or twice daily depending on the indication. When patients abruptly stop taking propranolol, they may experience exacerbations of angina and myocardial infarctions.

Mechanism of Action · 1 Eintrag

Propranolol is a nonselective β-adrenergic receptor antagonist. Blocking of these receptors leads to vasoconstriction, inhibition of angiogenic factors like vascular endothelial growth factor (VEGF) and basic growth factor of fibroblasts (bFGF), induction of apoptosis of endothelial cells, as well as down regulation of the renin-angiotensin-aldosterone system.

Biological Half-LifeThe elimination half-life of propranolol is approximately 8 hours. The plasma half-life of propranolol is 3 to 6 hours.
Metabolism/Metabolites · 2 Einträge

Propranolol undergoes side chain oxidation to α-naphthoxylactic acid, ring oxidation to 4’-hydroxypropranolol, or glucuronidation to propranolol glucuronide. It can also be N-desisopropylated to become N-desisopropyl propranolol. 17% of a dose undergoes glucuronidation and 42% undergoes ring oxidation.

Propranolol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-Trihydroxy-6-[1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-yl]oxyoxane-2-carboxylic acid.

FDA Pharmacological Classification · 6 Einträge

9Y8NXQ24VQ

PROPRANOLOL

Mechanisms of Action [MoA] - Adrenergic beta-Antagonists

Established Pharmacologic Class [EPC] - beta-Adrenergic Blocker

Zugehörige Reaktionen

17
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 10485
HRID 10485als Produkt
Reaktionsgleichung von HRID 35665
HRID 35665als Produkt
Reaktionsgleichung von HRID 231910
HRID 231910als Produkt
Reaktionsgleichung von HRID 328884
HRID 328884als Produkt
Reaktionsgleichung von HRID 328886
HRID 328886als Produkt
Reaktionsgleichung von HRID 328887
HRID 328887als Edukt
Reaktionsgleichung von HRID 867506
HRID 867506als Edukt
Reaktionsgleichung von HRID 892129
HRID 892129als Edukt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Agilent XCT

Electrospray ionization

formic acid (5.3nM)

Dissociation Constants · 3 Einträge

9.53

9.45

9.42

Collision Cross Section · 4 Einträge

162.5 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID3021198]

161.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

162.7 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

166.22 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
163 · 163-164 °C
Siedepunkt
402.6 °C · 402.6°C (rough estimate)
Dichte
1.028 · 1.0280 (rough estimate)
Brechungsindex
1.55 · 1.5500 (estimate)
storage temp.
-20 °C · -20°C Freezer, Under inert atmosphere
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
13.84 · 13.84±0.20(Predicted)
Farbe
White to Off-White
Wasserlöslichkeit
80.99 mg/L · 80.99mg/L(25 ºC)
InChI
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
InChIKey
AQHHHDLHHXJYJD-UHFFFAOYSA-N
SMILES
C(NC(C)C)C(O)COC1=C2C(C=CC=C2)=CC=C1
CAS Datenbank
525 · 525-66-6
NIST chemische Informationen
Propranolol(525-66-6)
EPA chemische Informationen
2 · 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- (525-66-6)
Adverse Effects · 2 Einträge

Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

Common side effects of using propranolol include bradycardia, gastrointestinal issues, abdominal pain, nausea, erectile dysfunction, and wheezing/bronchospasms. Propranolol use can also cause drowsiness, fatigue, and cold extremities. Some extreme side effects to be aware of include allergic reactions, insulin resistance, and hallucinations. Prescribers need to explain and discuss all of the side effects before giving patients a prescription for propranolol.

Toxicity SummaryIngestion of greater than 1 g of propranolol in 24 hours can potentially be lethal and lead to profound bradycardia, bradyarrhythmia, hypotension, bronchospasm.
Drug Induced Liver Injury · 6 Einträge

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

propranolol

Inderal®

Beta blockers

3

less-DILI-concern drugs

Effects During Pregnancy and Lactation · 2 Einträge

◉ Summary of Use during Lactation

◈ What is propranolol?

USGS Health-Based Screening Levels for Evaluating Water-Quality · 3 Einträge

Propranolol

Pharmaceutical

Smith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP

EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Propranolol

0.7

3.0

The recommended dose is 10 mg to 30 mg propranolol hydrochloride three or four times daily before meals and at bedtime.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 30 mg/day, Lowest Therapeutic Dose (LTD): 0.4 mg/kg-day, and Screening Dose: 0.0001 mg/kg-day.

1-Aug-15

Sicherheitsdaten

hs_code
2922509090

Propranolol is a beta-Adrenergic Blocker. The mechanism of action of propranolol is as an Adrenergic beta-Antagonist.

PROPRANOLOL

MeSH Pharmacological Classification · 4 Einträge

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs used to cause dilation of the blood vessels.

Absorption, Distribution and Excretion · 4 Einträge

Patients taking doses of 40mg, 80mg, 160mg, and 320mg daily experienced Cmax values of 18±15ng/mL, 52±51ng/mL, 121±98ng/mL, and 245±110ng/mL respectively. Propranolol has a Tmax of approximately 2 hours, though this can range from 1 to 4 hours in fasting patients. Taking propranolol with food does not increase Tmax but does increase bioavailability.

91% of an oral dose of propranolol is recovered as 12 metabolites in the urine.

The volume of distribution of propranolol is approximately 4L/kg or 320L.

The clearance of propranolol is 2.7±0.03L/h/kg in infants <90 days and 3.3±0.35L/h/kg in infants >90 days. Propranolol clearance increases linearly with hepatic blood flow. Propranolol has a clearance in hypertensive adults of 810mL/min.

Tissue LocationsLiver
Cellular LocationsMembrane
Metabolite PathwaysPropranolol Action Pathway

Verwendung und Herstellung

Uses · 2 Einträge

Used as a beta-blocking agent (antihypertensive drug); [Kanerva, p. 1830]

Use (kg) in Switzerland (2009): >750

Use ClassificationPharmaceuticals

Anwendungen

BeschreibungPropranolol was responsible for sensitisation of workers in drug synthesis. In one case, epichlorhydrin was used for the production of both propranolol and oxprenolol.

VerwendenCardiac depressant (anti-arrhythmic); anti-adrenergic (β-receptor).

Vor- und nachgelagerte Produkte

Nachgelagerte Produkte

Propranolol Impurity[2-Hydroxy-3-(naphthyloxy)propyl]isopropylammoniumchlorid

Ergänzende Hinweise

DefinitionChEBI: A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.